Go Back to Match Results for "trials"

A Phase 1 Study Of Ramucirumab a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors Including CNS Tumors
Study Overview
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Study Description
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Additional Information
- IRB Number: 1511807264 (PHO-LILLY-CROOP-ADVL1416)
- Research Study Identifier: TX5861
- Principal Investigator: James Croop, MD, PhD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required